Navigation Links
Vion Pharmaceuticals Enters into Agreement to Conduct a Phase I/II Clinical Trial of Cloretazine(R) in Combination with Induction Therapy in Poor Prognosis AML Patients
Date:9/22/2008

i-Calmettes has been able to keep a humanist approach to its mission by putting patients at the heart of the treatments and decisions that concern them. Each year, more than 1,200 staff members treat over 19,000 patients at the Institut. Research activities are undertaken by a critical mass of more than 200 scientific staff personnel.

About GOELAMS

The GOELAMS is a large multi-center cooperative group that includes 49 centers in France. The focus of the group is clinical and translational research on acute leukemia and lymphomas. The group is involved in many academic clinical trials and also sponsors some trials. It has set up a network of biologists in order to facilitate the use of new technologies and biologic markers in a multi-center setting, as well as a centralized cell repository. The trial described above is part of a large AML frontline therapy program. Two Phase III trials are currently ongoing for patients with favorable and intermediate-risk AML.

This news release contains forward-looking statements. Such statements are subject to certain risk factors which may cause Vion's plans to differ or results to vary from those expected, including Vion's potential inability to file a New Drug Application or obtain regulatory approval for its products, particularly laromustine (Cloretazine (VNP40101M)), delayed or unfavorable results of drug trials, the possibility that favorable results of earlier preclinical studies, clinical trials or interim clinical trial data are not predictive of safety and efficacy results in later or final clinical trials, the need for additional research and testing, the inability to manufacture product, the potential inability to secure external sources of funding to continue operations, the inability to access capital and funding on favorable terms, continued operating losses and the inability to continue operations as a result, the delisting of the Company's common stock from the Nasdaq Capital Market and a vari
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2009)... 15 Estill Medical Technologies, Inc., a family-owned ... and IV Fluid Infusion Warmer , a patented medical ... military and emergency responders to lessen ... CALSTAR 6 Unit of South Lake Tahoe as the ... Year Award." ,, CALSTAR is a California-based ...
(Date:12/15/2009)... N.J., Dec. 15 HealthLeaders-InterStudy and Fingertip ... directors expect to cover Pfizer,s tanezumab if it ... Tanezumab, which is expected to be the first ... intravenously under medical supervision, will likely be covered ... benefit according to surveyed pharmacy directors. According to ...
(Date:12/15/2009)... Biotech Ltd. ( SVA),a leading provider of ... Yin, Chairman, President & CEO, was selected ... of 18 nominees for China,s 2009 Economic,Man-of-the-Year. ... Man-of-the-Year is the country,s most influential and,well-known ... "Oscar Award of the,Chinese Economy." The award ...
Breaking Medicine Technology:Thermal Angel Blood Warmer Recognizes CALSTAR 6 With Distinguished Emergency Responder Award 2Thermal Angel Blood Warmer Recognizes CALSTAR 6 With Distinguished Emergency Responder Award 3Thermal Angel Blood Warmer Recognizes CALSTAR 6 With Distinguished Emergency Responder Award 4Majority of Surveyed Pharmacy Directors Expect To Cover Pfizer's Tanezumab If It Is Approved for the Treatment of Chronic Pain 2Majority of Surveyed Pharmacy Directors Expect To Cover Pfizer's Tanezumab If It Is Approved for the Treatment of Chronic Pain 3Sinovac's CEO Weidong Yin Nominated for China Central Television's Prestigious Economic Man-of-the-Year Award 2Sinovac's CEO Weidong Yin Nominated for China Central Television's Prestigious Economic Man-of-the-Year Award 3ETEX Corporation Announces Distribution Agreement with Alphatec Spine 60809 1ETEX Corporation Announces Distribution Agreement with Alphatec Spine 60809 2ETEX Corporation Announces Distribution Agreement with Alphatec Spine 60809 32009 Cedars Sinai Board of Governors Gala Sponsored by Lexus Raises Over 242 6 Million 60805 12009 Cedars Sinai Board of Governors Gala Sponsored by Lexus Raises Over 242 6 Million 60805 22 children suffering from adrenoleukodystrophy saved thanks to the ELA Association 60804 12 children suffering from adrenoleukodystrophy saved thanks to the ELA Association 60804 22 children suffering from adrenoleukodystrophy saved thanks to the ELA Association 60804 32 children suffering from adrenoleukodystrophy saved thanks to the ELA Association 60804 4
... in Journal Molecular Vision -, - Results Show Good ... ... MIAMI, June 3 OPKO Health, Inc. (Amex: OPK ... Vision demonstrates that bevasiranib, its siRNA (small,interfering RNA) agent is ...
... WORTH, Texas, June 3 Wound Care,Innovations, LLC, ... Software Corporation (OTC Bulletin Board: MBSB)) announced,today that ... the clinical,performance of their advanced wound care collagen ... major problem in the elderly and,compromised patients. It ...
Other Medicine Technology:Newly Published Study Shows OPKO's siRNA Bevasiranib Is Taken Up by Target Tissues in the Eye 2Newly Published Study Shows OPKO's siRNA Bevasiranib Is Taken Up by Target Tissues in the Eye 3Wound Management Technologies, Inc. Announces Evidence Based Study 2
(Date:12/15/2009)... 15 North American application activity for ... year-over-year, according to the MIB Life Index(SM) ... over the past three months have lifted year-to-date ... -1.6%, to flat at November,s close, -0.1%. ... in the benefits available from life insurance," says ...
(Date:12/15/2009)... links chronic obstructive pulmonary disease, or COPD, with increased ... the body,s immune system. , The University of ... of the immune system,s role in COPD, a serious, ... Americans with wheezing, shortness of breath, chest tightening and ... are to find better ways to detect and treat ...
(Date:12/15/2009)... taught to recognize symptoms will call for help, experts ... disability could be reduced by teaching children how to ... call 911 immediately, a new study shows. , Emergency ... symptoms can limit the extent of brain damage and ... Defeating Stroke (KIDS) project included 515 sixth graders in ...
(Date:12/15/2009)... opportunity for the unemployed or those needing additional income... known as ... , ... Orlando, FL (PRWEB) December 15, 2009 -- ... spreading holiday cheer and good will that is going to stick ... opportunity for out of work Americans to get back to the ...
(Date:12/15/2009)... of cardiovascular event, suicide goes up within a ... Dec. 15 (HealthDay News) -- Emotional stress can ... risk for cardiovascular events and suicide, a new ... 168,584 Swedish men diagnosed with prostate cancer between ... percent) experienced a cardiovascular event within a year ...
Breaking Medicine News(10 mins):Health News:MIB Life Index Reports North American Life Insurance Activity Up 3.9% in November 2Health News:MIB Life Index Reports North American Life Insurance Activity Up 3.9% in November 3Health News:Immune cell activity linked to worsening COPD 2Health News:Immune cell activity linked to worsening COPD 3Health News:Boosting Kids' Stroke IQ May Save Lives 2Health News:RPS Worldwide Launches Affiliate Program -- The Collection Agency That Gives Christmas Back, Rather Than Take it Away 2Health News:RPS Worldwide Launches Affiliate Program -- The Collection Agency That Gives Christmas Back, Rather Than Take it Away 3
... Skin Cancer Screenings And Education about Skin Cancer PreventionSKILLMAN, ... & Johnson Consumer Companies, Inc., announces its second year ... Healthy Skin" tour. The free skin cancer screening ... of New York City,s Grand Central Terminal, and will ...
... in treatment for women, signal need to change stroke ... traditional stroke symptoms are well known and include a ... of the body, trouble talking, loss of vision, or ... be paying attention to something else, says Lynda Lisabeth, ...
... drinking enough water are to blame.ANN ARBOR, Mich., May ... her daughter,s daycare saying that 3-year-old Emma was complaining ... be a condition often associated with middle aged men: ... pain and saying that her back hurt her," says ...
... and others? What can I do to prevent spreading swine ... related to the threatening pandemic of "Swine Flu", where time ... Internet News Distribution Channel FEEDZILLA updates news and information around ... the Flu" is available as a widget to be installed ...
... LEAWOOD, Kan., May 4 Why are some people ... others find themselves paralyzed and frustrated by change? As ... continues to create vast changes, the ability to adjust ... and Adapt" ( published by iUniverse ) ...
... 2013, according to Millennium Research GroupWALTHAM, Mass., May 4 ... Markets for Reprocessed Devices 2009, hospitals ... the global economic crisis and the rising cost of ... therefore increasingly purchasing lower-priced products, such as reprocessed devices, ...
Other Medicine News:Health News:AVEENO(R) Announces Kick-Off of The Skin Cancer Foundation's 2nd Annual 'Road to Healthy Skin' Tour Presented by AVEENO(R) and Rite Aid 2Health News:AVEENO(R) Announces Kick-Off of The Skin Cancer Foundation's 2nd Annual 'Road to Healthy Skin' Tour Presented by AVEENO(R) and Rite Aid 3Health News:AVEENO(R) Announces Kick-Off of The Skin Cancer Foundation's 2nd Annual 'Road to Healthy Skin' Tour Presented by AVEENO(R) and Rite Aid 4Health News:Women More Likely to Experience Non-Traditional Stroke Symptoms 2Health News:Women More Likely to Experience Non-Traditional Stroke Symptoms 3Health News:Kidney Stones in Children on The Rise, U-M Expert Says 2Health News:Kidney Stones in Children on The Rise, U-M Expert Says 3Health News:'Relearn, Evolve, and Adapt': Interdisciplinary Model for Thought Involves Psychology, Business, System Dynamics 2Health News:Reprocessed Device Market Booming During the Economic Crisis 2Health News:Reprocessed Device Market Booming During the Economic Crisis 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: